Pear Therapeutics raises $80M; finds cost savings of $2,150 per patient with opioid use disorder
Conclusion: reSET‑O initiation was associated with fewer inpatient, ED, and other clinical encounters, increased case management/rehabilitative services, and lower net costs over six months.
News in Context:
The FDA clears Somryst, Pear’s digital therapeutic to treat chronic insomnia
A call to action: We need the right incentives to guide ethical innovation in neurotech and healthcare
New report: Empowering 8 Billion Minds via Ethical Development and Adoption of Neurotechnologies
Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse
Pear Therapeutics raises $50M to develop and market a portfolio of digital therapeutics for mental health
The post Pear Therapeutics raises M; finds cost savings of ,150 per patient with opioid use disorder first appeared on SharpBrains.
Source: SharpBrains - Category: Neuroscience Authors: SharpBrains Tags: Brain/ Mental Health Technology & Innovation cost savings digital therapeutics neurobehavioral therapy opioid use disorder Pear Therapeutics reSET-O SoftBank Source Type: blogs
More News: Alcoholism | Brain | Emergency Medicine | Insomnia | Insurers | Laboratory Medicine | Medicaid | Medical Ethics | Men | Neurology | Neuroscience | Neurosurgery | Pathology | Psychiatry | Rehabilitation | Study | Substance Abuse | Training | Universities & Medical Training